ApoGraft - Cellect Biotechnology

Drug Profile

ApoGraft - Cellect Biotechnology

Alternative Names: ApoGraft; Mobilised peripheral blood cells - Cellect Biotechnology; Mobilised peripheral blood product - Cellect Biotechnology

Latest Information Update: 02 Mar 2017

Price : $50

At a glance

  • Originator Cellect Biotechnology
  • Class Cell therapies
  • Mechanism of Action Cell replacements; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Graft-versus-host disease

Most Recent Events

  • 22 Feb 2017 Immunogenicity data from a clinical trial in Healthy volunteers released by Cellect Biotechnology
  • 22 Feb 2017 Cellect Biotechnology completes a clinical trial trial in Healthy volunteers in Israel
  • 16 Jan 2017 Cellect Biotechnology receives patent allowance for engineered regulatory immune cells in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top